STORY FROM: Drugs & Medical Devices
FDA to Add New Warnings to Abilify Following Reports of Compulsive, Uncontrollable Urges
May 3, 2016
WASHINGTON, D.C. — The U.S. Food and Drug Administration says it is adding new warnings to the antipsychotic drug aripiprazoele, marketed as Abilify, Abilify Maintena and Aristada, following reports of compulsive or uncontrollable urges to gamble, binge eat, shop, and have sex.
According to the May 3 Drug Safety Communication, those uncontrollable urges were reported to have stopped when the patients discontinued the drug or the dose was reduced. The FDA noted that the impulse-control problems are rare, but could result in harm to the patient and others if not recognized.
“Although pathological gambling is listed as a reported side ...